

Cambridge University Press

978-0-521-25464-9 - The Consequences of Chromosome Imbalance: Principles, Mechanisms, and Models

Charles J. Epstein

Index

[More information](#)

 Index

- abnormalities: correction in trisomic mouse fetuses, 232; mechanisms involved in aneuploidy-associated postmorphogenetic phenotypic, 376; receptors and genetic, 108–12
- aborted fetuses, chromosomal abnormalities in spontaneously and therapeutically, 3, 5
- abortion, aneuploidy and spontaneous, 5–6
- acetylcholinesterase activity, 137–8
- activation in interspecific hybrid cells, 129, 131
- aging, Alzheimer disease and trisomy 21 and, 309–11
- ALA; *see* aminolevulinic acid (ALA)
- alleles, suppression of second set of, 82
- Alzheimer disease, 263, 300, 306–11
- aminolevulinic acid (ALA), porphyrias and synthesis of, 96
- AMP, *see* cyclic AMP
- aneuploid cells, regulatory disturbances in, 135–40, 375
- aneuploid embryos (human), death of, 3
- aneuploidy: abnormalities from, 86; acquired, 351, 353, 355–65; altered cell-cycle hypothesis and, 175–7; autosomal (in mouse), 237–8, 241–6; causes of phenotypic changes associated with, 114; cell hybrid investigations and, 134–5; cell replication hypothesis and, 174–7; characters that remain unaltered in phenotype of double, 39; combined sex chromosome and autosomal, 23; defined, 9; dermoglephic changes and, 170–2; development and, 181; direct and indirect secondary effects of, 86; economic burden of, 5; effects of double, 28, 38, 39, 50; effects of X-chromosomal, 324; eukaryotic regulation changes and, 113–14; frequency at conception, 3; full vs. segmental, 33–5, 38, 81–2; gene dosage effects and, 65, 66, 76, 259–73, 283; genesis of, 235; imbalances due to, 100; incidence at age 40, 5; interactive effects of combination of segmental, 370; malignancy and acquired, 6; malignancy and constitutional, 346–7, 350; mechanisms responsible for abnormalities associated with, 76, 112, 373, 376; mechanistic basis for effects of, 6–8, 373; mechanism as focus of research on, 377; models for study of effects of, 378; mental retardation and, 5; morbidity and, 6; negative effects of, 143–5; nervous system and, 299–300; nonspecific effects of, 174–204, 278, 372; primary and secondary effects of, 85, 86; reasons for studying effects of, 379–80; receptor-mediated phenomena and, 103–4, 106–8, 374, 376; reductionist approach to understanding effects of, 7–8; regulatory systems and, 117, 143–5; relationships among mechanisms underlying phenotypic features of, 376; segmental, 23, 25, 28–9, 31–5, 38, 50, 81–2, 210, 220–1, 370; specificity of effects of, 39; syndromes from very small amounts of, 52; synergistic effect in double, 32–3; teratocarcinoma cells for studying, 233–4; *see also* names of specific aneuploid conditions
- animal models, 157–8, 201, 207, 235–6, 379; for chromosome-mediated gene transfer, 248–9; nonhuman primates as, 236–7; with single extra copies of particular genes, 248; for study of autosomal aneuploidy, 237–8, 241–6; for study of X-chromosomal aneuploidy, 244–6; for trisomy 21, 311–13, 315–23; *see also* names of specific animals
- Aniridia–Wilms tumor, 47
- antizymes: deficiencies of, 97; increase in, 98
- antimongolism, 159
- antisynndrome concept, 159–60, 161, 165, 167–70, 172–3
- antithrombin III, excess of, 98
- antitrypsin: abnormal increase in, 98; deficiency of, 97

Cambridge University Press

978-0-521-25464-9 - The Consequences of Chromosome Imbalance: Principles, Mechanisms, and Models

Charles J. Epstein

Index

[More information](#)478 *Index*

- arylhydrocarbon hydroxylase: regulation of, 123–5
- autogenous regulation, 83
- autosomal dominant conditions, variability in expression of, 183
- autosomal gene dosage compensation, absence in mammals, 82; presence in *Drosophila*, 81–2
- autosomal recessive conditions, variability in expression of, 184
- bacteria, model of genetic regulation in, 114; *see also Escherichia coli*
- barley, regulatory disturbances and aneuploidy in, 140–1
- Caenorhabditis elegans*, 122–3
- canalization, 181, 185
- cancer: aneuploidy and, 253, 345; chromosome imbalance and, 375; dup(lq) and, 349–50; origin of, 345; specific chromosome regions and, 344–6; teratocarcinomas in mouse to study, 232; *see also* malignancy; tumorigenicity
- carcinogenesis, retinoblastoma and “two hit” theory of, 347–50; *see also* oncogenes; tumorigenicity
- C complementation group (*pccC*) of propionyl coenzyme A carboxylase deficiency, 84
- cell cycle, aneuploidy and, 174–6
- cell doubling times in aneuploid cells, 175–6
- cell hybrids, 127–35; potential problems with studies using, 136
- cells: abnormal cells stimulating division of normal, 363; adhesion of, 151, 152, 154, 298; aggregation of, 281–2; lack of permanence of trisomic mouse embryonic and fetal lines of, 233; polyploid, 195–204; sensitivity to mutagenic or carcinogenic agents of trisomic, 273, 274–80
- cell surface: constituents, 75; ploidy and area of, 196
- cell transformation, 277–9
- cellular determination distinguished from cellular expression and differentiation, 134
- cellular differentiation, basic mechanisms of, 122
- cellular interactions, morphogenesis and, 151–5, 298
- cellular mosaicism, 96
- cellular proliferation: effect of monosomy on (in mouse), 219; retardation of development and, 174–7; trisomy 21 and, 272–3
- cellular proteins, regulatory disturbances and, 140–3; *see also* proteins
- cell volume, ploidy and, 196
- chicken: triploidy in, 201; wing bud experiments, 155–6
- chimeras in mouse, 221, 224–7, 229–32, 234, 318
- Chinese hamster ovary (CHO) cells: activity of RNA polymerase II in hybrid, 84; substrate adhesion molecules (SAM) and, 152
- chromosomal abnormalities and defects: developmental consequences of two different, 39; genetic imbalance and, 369; in human embryos, fetuses, and newborns, 3–5; meningiomas and, 363; phenotypes associated with specific, 49–50; in plants, 140–1
- chromosomal banding, 47
- chromosomal changes, primary vs. secondary, 363–5
- chromosome complements: extra sets of haploid, 195–204; in near-diploid and near-tetraploid hybrid cells, 127
- chromosome identification, difficulties due to lack of precise, 23
- chromosome imbalance, *see* imbalance
- chromosomes: artificial, 248; causes of symptoms of imbalance of, 114; cell cycle and number of, 176–7; cell phenotype and number of, 129; double aneuploidy involving whole, 22–3; effect on cell proliferation of X and Y, 175; effect of triplicated, 181–2; homologous pairing at meiosis of X and Y, 334; imbalance of regions of, 39, 44, 65, 361; increasing phenotypic abnormality with increased number of specific, 61; isolation and perpetuation of translocation, 210; lethality and length of, 193; loss of (in hybrid cell cultures), 127–8; mitotic rate and extra, 175; monobrachial homology in, 207; Ph¹, 362; regions with many active loci, 193; relationship between specific phenotypic feature and imbalance of, 44; repair of aberrations of, 275; Robertsonian fusion, 207–9; significance of parental source of, 189–90, 204; size of, 193–4; symbols for metacentric, 209; triplication of identical vs. non-identical, 186–7; *see also* sex chromosome anomalies; X chromosome(s); Y chromosome(s)
- chromosome segment(s): addition or loss of, 9; cancer and breakpoints involving, 346; double aneuploidy of, 23, 25, 28–9; effect of deletions of, 42–3; effect of

Cambridge University Press

978-0-521-25464-9 - The Consequences of Chromosome Imbalance: Principles, Mechanisms, and Models

Charles J. Epstein

Index

[More information](#)

- increased length of duplicated, 40–1, 50, 51; features identified with aneuploidy for specific, 43; homologous X and Y, 334–6; inserted into X chromosome, 99
- chromosome 7 (mouse), 99, 125–6
- chromosome 8, Langer–Giedion syndrome and, 54
- chromosome 11: Aniridia–Wilms tumor and, 47
- chromosome 13: digit anomalies and, 172; duplication of “proximal” and “distal” segments of, 34–5; limb buds and, 172; phenotypic features of trisomy of, 18; phenotypic mapping of, 44, 45–7; retinoblastomas and changes in, 347, 348, 350
- chromosome 15: Prader–Willi syndrome and abnormalities of, 52–3; tetrasomy of, 56–8; translocations involving, 52
- chromosome 15 (mouse), 355–9
- chromosome 16 (mouse), 312–13, 315–18, 320–3
- chromosome 18: duplications of segments vs. full trisomy of, 38; immunoglobulin A (IgA) and abnormal, 139–40; phenotypic mapping of, 44–5
- chromosome 21: Alzheimer disease and, 308–9; Down syndrome region of, 255–9, 312; effects of unbalancing loci on, 259–71; enzymes of purine biosynthetic pathway and, 269–70; leukemogenesis and, 288; locus for interferon- α receptor (*IFRC*) on, 263–9; map of, 253–5; mouse chromosome 16 and, 312–13; *PFKL* region on, 256; phosphofructokinase L (liver) subunit and, 270; *PRGS* region on, 256; *SOD 1* region on, 256; *see also* trisomy 21 (Down syndrome)
- chromosome 22: DiGeorge syndrome and, 53–4; duplications involving, 33–4
- cleavage: effect of monosomy on (in mouse), 219; genetically determined alteration in rate of, 189
- coenzyme A carboxylase deficiency, 84
- collagen disorders, 150
- conceptions not surviving beyond implantation, 3
- congenital anomalies and malformations: cardiac, 297–9, 315; chromosome defects and, 49–50; in identical twins, 371
- control mechanisms for gene product concentration, concept of gene dosage effects and, 66
- countercharacters, 161, 165, 167, 372
- countertype concept, 159–60, 161, 165, 167–70, 172–3
- critical regions for phenotypic features, 50–2
- cyclic AMP (cAMP), trisomy 21 fibroblasts and, 279–80
- cystine from lysosomes, 101
- cystinuria, 100–1
- cytogenetic lesions, variability in expression of some, 15, 18
- deletions, 375; autosomal dominant conditions and, 114; of chromosome segments, 42–3; cri-du-chat syndrome and, 52; defined, 9; and duplications of same segment, 172–3; Langer–Giedion syndrome and, 54–5; lethal albino (in mouse), 125–6; malignancy and, 247–8, 361–3; mechanisms for variability in states associated with, 375–6; Miller–Dieker syndrome and, 54; in mouse, 125–6, 210, 220–1; phenotype of X chromosome, 336; phenotypic effects of small, 55; retinoblastoma and, 347–8; severity of effects of, 176; uniplex state resulting from, 65; Wilms tumor and, 47, 347
- development: aneuploidy and, 181; aneuploidy and retardation of, 177–80; cellular interactions and, 151, 298; control of, 371; of form, 155; genetics and mechanism of, 44; meaning of retarded, 179; processes in embryonic, 155; temporal relationships in, 106; transcriptional control in sequential gene activation during, 118
- developmental buffering, 181
- developmental homeostasis, 7
- developmental regulatory disturbances, clinical observations and, 138–40; *see also* differentiation; morphogenesis
- differentiated cells, 155; control of expression of genes in, 118
- differentiated functions: inappropriate, 136–7; regulator substances that suppress, 131
- differentiation: cell hybrids for analysis of, 131; cellular, 122, 232–3; cellular determination distinguished from, 134; development and maintenance of, 117–18; enzymes in hybrid cells and, 129; *see also* morphogenesis
- digital dermal ridge patterns, 170–2
- dihydrobiopterin, 309
- DNA: injection into just-fertilized egg, 247; mitotic cycle time and content of, 176; synthesis of, 272
- DNA probes, recombinant, 254, 335, 377
- Down syndrome, *see* trisomy 21 (Down syndrome)

Cambridge University Press

978-0-521-25464-9 - The Consequences of Chromosome Imbalance: Principles, Mechanisms, and Models

Charles J. Epstein

Index

[More information](#)480 *Index*

- Drosophila*, 120; effects of combining individual segmental aneuploidies in, 100; effect of size of aneuploid segment in, 191–3; gene dosage effect studies in, 78, 144; genetic mapping in, 78; lethal aneuploidy in, 191; nonlethal aneuploidy in, 192; temporal genes in, 119–21; triploid, 202; trisomic, 141; type and countertype and, 159
- duplication(s): defined, 9; and deletions of same segment, 173; malignancy and, 360; in mouse, 210, 220–1; phenotypic changes and segmental, 40–1; for proximal and distal segments of 22q, 33–4; severity of effects of, 176
- EBV, *see* Epstein–Barr virus (EBV)
- EGF, *see* epidermal growth factor
- electrophoresis, 82, 141–3
- embryogenesis, teratocarcinomas for study of, 232
- environmental influences on expression of genotypes, 184–6
- enzyme defects and deficiencies: association with specific diseases, 93; dominant, 93, 99; heterozygosity and, 86, 92–7; metabolic effects in mammals heterozygous for, 92; monosomy and, 98; stress and, 99–100
- enzyme induction, indeterminate patterns in heterozygotes, 125
- enzyme-mediated metabolic reactions, potential effects of aneuploidy on, 89
- enzyme reactions, effects of altering enzyme concentration and, 86–9
- enzymes: concentration during development, 119; control of synthesis of, 119; development and, 119, 122; disease from reduced activity of, 93–6; effects of increased activity of, 98–9; as gene products, 75; heterozygous deficiency of, 87, 92–3, 96; individual changes in activity of, 100; loci that code for, 76; metabolic changes in heterozygotes for deficiency of, 87; phenotypic effects of changes in concentrations of, 374; rate-limiting, 86–9; X-linked, 98, 203
- epidermal growth factor, 171
- epidermal growth factor receptor gene, 111
- epithelial cell growth, proteins inhibiting, 169
- Epstein–Barr virus (EBV), amount of mRNA and number of genome copies of, 76
- Escherichia coli*: lactose operon repressor in, 113; metabolic flux and rate-limiting enzyme activity in, 98; transcriptional regulation in, 78
- eye development, abnormalities of, 172
- extinction of differentiated cell functions in hybrids, 127, 131
- facteur thymique serique (FTS), trisomy 21 and, 295–6
- familial hypercholesterolemia as defect in transport system, 109
- female human embryos, genetic imbalance in germ cells of, 331
- fetuses (human), chromosomally abnormal, 5
- fibroblasts, 286; aggregation of trisomic- and normal-derived, 281–2; comparison of diploid and trisomic, 141; human gene products and, 75; induction of alkaline phosphatase activity in, 279; induction of cyclic AMP and trisomy 21, 279–80; peptide and polypeptide synthesis in, 142–3; response to isoproterenol, 279, 304; trisomy 21 and in vitro proliferation of, 272–3
- fingerprints, *see* digital dermal ridge patterns
- fingers, 171–2
- flux, metabolite, 86–90
- fructose intolerance, hereditary, 93
- FTS, *see* facteur thymique serique (FTS)
- gene dosage: experiments on, 131–4; product synthesis and, 76; relationship between development of aneuploid phenotype and, 55, 299; results of altered, 131; tetraploidy and, 199–200
- gene dosage compensation: autosomal, 82, 84; in *Drosophila*, 84; special type of (for prokaryotes), 83
- gene dosage effects, 129, 143; aneuploid and diploid cell differences and, 107–8; in bacteria, 78; in cell hybrids, 127; direct tests for, 66; in *Drosophila*, 78, 144; duplications and, 360; in *E. coli*, 113; failure of manifestation of, 84; glutathione reductase in trisomy 8 red cells, 361; human, 75–6; mapping by, 377; in mouse, 76, 357, 360; mRNA concentration and, 76; oncogene activation and, 362; in plants, 78; primary and secondary, 85; quantitative, 373; reciprocal, 167; regulatory effects and, 143–5, 360; studies to assist in localization of genes and, 66; trisomies and, 360; in trisomy 21, 259–73, 283; tumor-associated non-random chromosome changes and, 357
- gene expression: governed by repressors (in bacteria), 114; inappropriate, 138; regulatory substances and, 131–3

- gene loci, mapping of, 47, 49, 66; *see also* mapping
- gene products: altered concentrations of, 303, 373–4; gene dosage effects concept and regulatory systems for, 66; red cells and fibroblasts and human, 75; significance of aneuploidy-produced changes in synthesis of, 85
- gene(s): effect of dosage of regulatory, 117, 120; growth and number of, 170; lethal, 190; proximate, 119–20; sensor, 123–4; structural, 119; temporal 119–20, 122–3; trans acting, 120, 122
- genetic defects and abnormalities: affecting receptors, 108–12; disease and environment and, 95
- genetic imbalances, effects of, 86, 369
- genetic instability, oncogene activation and, 364
- genetic regulation, 135–45; models of (in eukaryotes), 115–19
- gene transfer, 247; chromosome-mediated, 248
- genomes: mapping of, 377; unbalanced, 372
- globin, genes for alpha-, 146, 148–9
- glucose–galactose malabsorption, 101
- glutathione peroxidase, 261–2
- glycolysis: PFK and, 271; rate-limiting enzyme in, 270
- glycolytic pathway, 99
- gonadal dysgenesis, 253; monosomy X and, 330–2
- gradients of morphogen concentrations, 155–7, 172
- growth: aneuploidy and intrauterine retardation of, 178–9; control of longitudinal somatic, 333; diploid and trisomic cells and differential in, 176; inhibition of epithelial cell, 169; *see also* development; morphogenesis
- heme biosynthesis, pathway of, 93
- hemoglobins in human newborns with trisomy 13, 46, 138–9
- heterokaryons, 126
- heterozygosity: abnormalities and, 86, 92–7, 100, 101, 109; antienzyme deficiencies and, 97; cystinuria and, 100–1; glucose–galactose malabsorption and, 101; iminoglycinuria and, 101; phenylketonuria and, 92–3; renal glycosuria and, 101
- heterozygote tissues, mosaic nature of, 100
- hexasomy 21, mosaic, 56
- hexokinase, duplication of chromosome arm 10p and increase in red cells, 99
- homeostasis, disruption of developmental, 180–3
- homology between human and animal genomes, 236
- hybrids, *see* cell hybrids
- IFN- α , *see* interferon- α (IFN- α)
- IFRC, *see* interferon- α (IFN- α) receptor (IFRC)
- IgG, *see* serum immunoglobulin
- IgM, *see* serum immunoglobulin
- imbalances: aneuploidy and, 100; of chromosome regions, 39, 44, 65, 167–8, 361; continuum of effects between single gene and whole chromosome, 55; developmental delay and chromosome, 178; geometric, 202, 204; in germ cells of female embryos, 331; lethality and, 192; lethality and active loci, 193; of loci, 372; in mouse (human aneuploid states and), 238, 240; neoplasia and chromosome, 375; production of phenotypic effect and degree of genetic, 373; of regulatory function, 360; variability in expression of chromosomal, 183; *see also* chromosomes, imbalance of regions of; genetic imbalances
- iminoglycinuria, 101
- immune system, 287, 288, 290–7
- immunodeficiency in trisomy 21, 288, 290–7
- immunoglobulin A (IgA), 139–40
- insulin binding to fat cells, 109
- integrating regulatory transcription units, 117
- intelligence quotients in phenylketonuria heterozygotes, 93
- interferon- α (IFN- α): intracellular polypeptides induced by, 264; sensitivity of trisomy-21 cells to, 265–9
- interferon- α (IFN- α) receptor (IFRC), 75, 154, 263–9
- interferon production by mitogen-stimulated cells, 260
- lac* operon, 117
- LDL receptors, *see* low density lipoprotein receptors
- lethality, 3, 189, 190–3, 195; aneuploidy-induced, 372; human 45.X, 342; of monosomy in mouse, 219; of monosomy X, 338–40; of segmental aneuploidy in mouse, 221; tetraploidy and, 199; of trisomy in mouse, 193–4, 212, 216, 231–2
- leukemia: chromosome aberrations and, 345; trisomy 21 and, 273, 283, 284–8
- ligand binding, receptor number and outcome of, 112
- ligand concentration, 102–4, 106–8

482 *Index*

- locus(i): balance between suppressor and repressor, 349, 360; comparative (man/mouse) mapping of, 238; phenotypic effects and genetic, 377; regulatory, 84, 143; terminology ("triplex," "uniplex") for number of copies of, 9–10
- low density lipoprotein (LDL) receptors, 109, 154
- lymphocytes: mouse T-cell, 356, 358–9; in trisomy 16 (mouse), 320; in trisomy 21, 175, 275, 277, 287, 290, 292, 294–5, 296–7
- maize, 120; gene dosage compensation in, 84
- male germ cells, two X chromosomes in, 332
- male meiosis, reactivation of second X chromosome during, 332
- malformations: characteristic combinations of, 182; genetic disturbances and pattern of, 50
- malignancy: aneuploidy and, 6, 9; chromosomal abnormalities and, 351; chromosomal changes and, 364; cytogenetic issues in, 344; trisomy 8 and, 351; *see also* leukemia; tumorigenicity in hybrid human cells
- mapping: fine-structure gene, 361; by gene dosage effects, 377; man/mouse comparative, 238, 312–13; meaning of term, 44; phenotypic effects to small chromosomal regions, 55; X-chromosome phenotypic, 336–7; *see also* phenotypic mapping
- masking: of chromosomal defects, 39; length of aneuploid segments and, 50; of phenotypic features, 43, 50
- mechanism as focus of research on effects of aneuploidy, 377
- melanin synthesis, tyrosine hydroxylase activity and Cattanach translocation and, 99
- meningiomas, chromosome aberrations and, 363
- mental retardation, aneuploidy and, 5
- metabolic flux, 86–9
- metabolic pathway(s): buffering capacities of, 93; disease reduction of activity of enzyme in a, 93–6; effects of altering enzyme concentrations and, 86–9
- metabolism, heterozygosity and inborn errors of, 92–3, 96, 97, 100, 101, 109
- metallothionein in yeast, 112
- monosomic cells, survival of somatic, 331; ligand interaction with receptors and, 102–4, 106–8
- monosomy: defined, 9; enzyme (or enzyme inhibitor) deficiency and, 98; human embryos with autosomal, 3; malignancies and, 361–3; mechanism for variability in states associated with, 375–6; in mouse, 189, 216, 219, 232; partial, 9; responses to ligand concentration and, 108; teratocarcinoma cells (mouse) for study of effects of autosomal, 233; uniplex state resulting from, 65
- monosomy 7, 363
- monosomy 22: DiGeorge syndrome and, 53–4; meningioma and, 363
- monosomy X (or XO), 253; cause of somatic manifestations of, 333; lethality of, 338–40; phenotype of, 330
- morphogen, 154–5, 167–9, 172
- morphogenesis, 8; cellular interactions and, 151–5; failure to map loci involved in, 357; hand, 170–2; limb, 155–8; products of genetic loci and, 50; *see also* differentiation
- morphogenetic processes, 122; interactions affecting, 370–3; interpretation of, 13
- mortality rate(s): autosomal trisomies and, 5; sex chromosome aneuploidy, 5
- mouse: albino deletions in, 126; autosomal aneuploidy in, 237–8, 241–6; Cattanach translocation and tyrosine hydroxylase synthesis in, 99; chimeras in, 221, 224–7, 229–32, 234, 318; chromosome characteristics in, 209; deletions in, 125–6, 210, 220–1; developmental lesions in, 216; duplications in, 210, 220–1; feral, 209; fetal survival and chromosome size in, 193–4; gene dosage effects in the, 76, 357, 360; limb bud experiments with, 157; methods for obtaining full chromosome aneuploidy in, 207–10; as model for human aneuploidy, 242–3, 312–13, 315–18, 320–3, 378–9; monosomies in, 189, 216, 219, 232; as regulatory system model, 123–5; segmental aneuploidy in, 210, 220–1; sex reversal gene in, 245–6; for study of nervous system, 243; teratocarcinomas as experimental systems in, 232–4; tetraploid thymoma in, 109–11; tetraploidy in, 198–9; tetrasomies in, 60, 109–10; 39-X, 340–2; transgenic, 247–8; triploidy in, 201, 203, 204; trisomic blood and lymphoid cells in diploid, 221; trisomies in, 141, 176, 188, 194, 207–9, 212, 216, 312–13, 315–18, 320–2; trisomy-13 or -16 stem cells in, 224; two translocation chromosomes in, 60; XO compared with human 45X, 343; XO female, 340–2

Cambridge University Press

978-0-521-25464-9 - The Consequences of Chromosome Imbalance: Principles, Mechanisms, and Models

Charles J. Epstein

Index

[More information](#)

Index 483

- mouse–Chinese hamster hybrid cells, 127
- mouse–human hybrid cells, mouse globin synthesis in, 129
- mouse lymphoma and leukemia, 355–61
- mouse trisomy 16, 216, 312–13, 315–18, 320–3
- muscle and muscle fibers in trisomy 21, 302–3
- mutations affecting cell surface constituents, 109, 154
- natural killer (NK) cell, 294–5
- nervous system: failure in mapping loci for organization and function of central, 377; mouse model for study of, 243; platelets as model for synaptosomes in, 281; trisomy 21 and, 299–300, 303–6
- neural cell adhesion molecule (N-CAM), 152–4
- neuronal degeneration, trisomy 21 and, 300
- Neurospora*, arginine pathway in, 90
- neurotransmission, trisomy-21 biochemical abnormalities and, 280, 304–5
- newborns with chromosomal abnormalities, 5
- nuclei, two or more unfused per cell, 126
- OCT, *see* ornithine carbamoyltransferase
- oncogenes: activation of, 362; deletions and monosomies and expression of, 362–3; familial renal carcinoma and, 355; gene dosage effects and expression of, 362; genetic instability and activation of, 364; translocation-inactivated, 357; translocations and, 353, 355, 364; *see also* carcinogenesis; tumorigenicity
- organogenesis, 8
- ornithine carbamoyltransferase (OCT), X-linked deficiency of, 96
- osteogenesis imperfecta, 150
- PAIS, *see* phosphoribosylaminoimidazole (PAIS)
- pattern formation, 155–8
- PCC deficiency, 84
- pentasomy of X chromosome, 61
- peptides, trisomy and, 141–2, 145
- PFKL, *see* phosphofructokinase (liver isoenzyme of) (PFKL)
- PHA, *see* phytohemagglutinin
- phenotypes: analysis of complex chromosomal aneuploidy, 165; association between specific portion of a chromosome and, 49; characters that remain unaltered in a double aneuploid, 39; composite, 28–9, 31–3, 39; derivation of, 23, 25; discriminating, 15; duplication of chromosome segments and changes in, 40–1; number of chromosomes and cellular, 129; pathogenesis of aneuploid, 372; principles governing development of aneuploid, 369–73; sources of variability in expression of, 19, 21; variability of, 371; variation among sibs in expression of, 19
- phenotypic characteristics and loci imbalances, 372
- phenotypic descriptors for syndrome delineation, 15
- phenotypic hybrid, 28
- phenotypic mapping, 43–7; basis for, 40
- phenotypic variability, 371; genetic factors in, 186–90; non-genetic factors in, 183–6
- phenylketonuria, 305; heterozygote detection, 92; IQ in heterozygotes for, 93
- phosphofructokinase (liver enzyme of) (PFKL), 254, 270–1
- phosphoribosylamine, regulation of formation of, 98
- phosphoribosylaminoimidazole synthetase (PAIS), 269–70
- phosphoribosylglycinamide synthetase (PRGS), 253–4, 269–70
- phosphoribosylpyrophosphate (PRPP) synthetase as X-linked enzyme, 98
- phytohemagglutinin (PHA), responses to, 290–2
- placentas: monosomy X and abnormal, 339–40; in mouse chimeras, 230
- plants: gene dosage compensation in, 81–2; gene dosage-dependent changes in protein content in, 200; gene dosage effects in, 78; mitotic cycle times in, 176; regulation disturbances and aneuploidy in, 140–2; trisomics among, 78; *see also* names of specific plants
- plasminogen, partial deficiency of, 96–7
- platelets in trisomy 21, 280–1
- platelet serotonin in trisomy 21, 280–1
- polyploidy: aborted human fetuses and autosomal, 3, 5; mechanisms and effects, 195–6
- porphyrias: dominantly inherited, 93–6; induction of ALA synthetase and, 96
- PRGS, *see* phosphoribosylglycinamide synthetase (PRGS)
- primates, 237
- protein molecules: dominantly inherited disorders and synthesis of structurally abnormal, 146; genetic determination of three dimensional structure of, 7
- proteins, 75; aneuploidy and reduction in specific, 145; deficiencies of structural, 149–50; gene dosage effects for genetic imbalances and data on, 76; significance

484 *Index*

- proteins (*cont.*)
 of changes in concentration of constituents of structural, 374; *see also* cellular proteins
- protoporphyrin, ferrochelatase in, 93
- PRPP synthetase, *see* phosphoribosylpyrophosphate (PRPP) synthetase
- psychological functions, enzymatic and transport systems changes that could affect, 374
- purine biosynthesis, control of, 98
- radiosensitivity, 275
- rats: cell hybrids from cells of, 128; compensation for loss of albumin gene in heterozygous, 83; triploidy in, 201
- receptors and receptor-mediated phenomena, 101–4, 108–12; aneuploidy and, 103–4, 106–12; developmental events and, 112; regulatory systems and, 125
- red blood cells: abnormal, 149–50; fibroblasts and, 75; glutathione reductase in trisomy-8, 361; human gene products and, 75; trisomic, 99, 361
- regulation, buffering systems for stable, 138
- regulator substances, trans-acting, 134, 375
- regulatory disturbances: analysis of cellular proteins and, 140–3; in aneuploid cells, 375; clinical observations and developmental, 138–40; to explain effect of aneuploidy, 174; gene dosage effects and, 143–5, 360; in nonmammalian aneuploid cells, 143–5
- regulatory loci, 84, 143–4
- regulatory models, 113–15, 115–19
- regulatory molecules, synthesis and action of, 116–17
- regulatory systems: additivity in trans-acting, 122; aneuploidy and, 117, 143–5; arylhydrocarbon hydroxylase, 123–5; difference between prokaryotic and eukaryotic, 115–16; mechanisms of, 131–4; molecular basis for eukaryotic temporal gene, 122
- renal glycosuria, 101
- repetitive sequence transcripts, 117
- repressors, gene expression in bacteria and, 114
- retinoblastoma: cellular genotype of, 348–9; 13q deletions and, 47–9; “two hit” theory of carcinogenesis and, 347–50
- RNA: gene dosage effects and messenger, 76; synthesis, 84; trisomic cells and concentration of, 272
- RNA polymerase II, 84
- RNA processing, posttranscriptional control at level of, 116
- SAM, *see* substrate adhesion molecules
- segmental chromosome imbalances, interaction of two, 33
- serotonin, *see* platelet serotonin in trisomy 21
- serum albumin, control of concentration of, 83
- serum immunoglobulin, 288
- sex chromosome aneuploidy, 244–6, 324–43; behavioral deviance and, 5; mortality rate and, 5; triploidy and, 202
- sex chromosome anomalies: abnormalities associated with, 177; in newborn humans, 5
- sib data, 18–19
- SOD-1, *see* superoxide dismutase-1
- sorghum, regulatory disturbances and aneuploidy in, 140–1
- steroid sulfatase (STS), 328–30
- stochastic factors causing variability, 184–5
- stress, heterozygous conditions and, 92
- STS, *see* steroid sulfatase (STS)
- substrate adhesion molecules, 152
- superoxide dismutase-1 (SOD-1), 75, 287; gene for, 254–9, 260–3; in trisomy 21, 256–9, 260–1, 275
- suppressor, oncogene activation by removal of cis-acting, 362
- SV40 T-antigen, 278
- syndrome delineation, phenotypic descriptors for, 15
- syndromes: autosomal dominant conditions and chromosome deletion, 114; cat-eye, 59; clinical features and diagnosis of chromosomal, 15, 18; cluster analysis in study of, 15; Cornelia de Lange, 55; cri-du-chat, 43, 51, 52; del (4p), 51; del (5q), 51; del (16q), 51; del (18q), 51; del (21), 159; delineation of, 15; DiGeorge, 42, 53; fetal alcohol, 178; Klinefelter, 332; Langer-Giedion, 54–5; length of aneuploid segment and manifestation of, 51–2; microphthalmia, 59; Miller-Dieker, 54; monosomy-21, 159; partial trisomy, 190; Prader-Willi, 52; Rubinstein-Taybi, 55; small-deletion, 52–5; trisomy-18, 51; trisomy-18p, 58; Turner, 253, 332–6, 337; unbalanced rcp(11;22), 59; variability of phenotypic features of chromosomal, 21; *see also* trisomy 13; trisomy 21 (Down syndrome)
- syntenies in man and mouse, 238
- T-cell oncogenesis, 358–9
- teratocarcinoma cell lines: aneuploidy in,

Cambridge University Press

978-0-521-25464-9 - The Consequences of Chromosome Imbalance: Principles, Mechanisms, and Models

Charles J. Epstein

Index

[More information](#)

- 232; chimeras with, 232; preparation of, 233–4
- tetraploid murine thymoma, 109–11
- tetraploidy: effects of (in mice), 198–9; gene dosage and, 199–200; lethal mechanisms of, 199; in liveborn human infants, 197
- tetrasomy: abnormalities associated with autosomal, 55–6; effects of, 33; relationship between effects of trisomy and, 59–60; as a special case of double aneuploidy, 33, 55; of X chromosome, 61
- tetrasomy 12p mosaic, 56
- tetrasomy 16 (in mouse), 60
- tetrasomy 18p, 58
- tetrasomy 21 mosaic, 56
- tetrasomy 22, 58–9
- thalassemia, 146, 148–9
- threshold phenomena in pathogenesis of phenotypic effects, 373
- thymus, 295, 320
- toes, 171–2
- tomato, gene dosage compensation in, 82
- transcription, activator gene for initiation of, 115
- transcriptional control in sequential gene activation during development, 118
- transcriptional regulation in *Escherichia coli*, 78; regulatory genes and, 117
- translocation chromosomes in mouse, 60
- translocations: Cattanach, 99; DiGeorge syndrome and, 54; effect of, 353; homozygous Robertsonian, 356; involving chromosome 15, 52; malignancies and, 351, 364; oncogenes and, 353, 355; *T(1;13)70H* (in mouse), 60
- transplanted tumors, disappearance of mouse trisomy 15 in serially, 359
- transport systems: familial hypercholesterolemia as defect of, 109; monosomies or deletions and, 101
- triplex, defined, 9–10
- triplex state, gene dosage effect and, 65, 66
- triploidy: animals in study of, 201–3; anomalies in human, 200; basis for difficulties in, 203–4; biochemical studies of, 201–2; in mouse, 201, 203, 204; sex chromosome aneuploidy and, 202–4
- trisomic blood and lymphoid cells in diploid mouse, 221
- trisomic cells, ligand interaction with, 102–4, 106–8
- trisomic lymphocytes, radiosensitivity of, 273, 275
- trisomic phenotypes, pathogenesis of, 374, 375
- trisomy(ies), 9; aborted human fetuses and autosomal, 3, 5; cell adhesion and, 154; in *Drosophila*, 141; lethality and, 190, 193, 195, 212, 216; for a metacentric chromosome, 33; mouse, 141, 176, 188, 194, 207–9, 212, 216, 312–13, 315–18, 320–2; phenotypic differences among, 175; polypeptides and, 145; relationship between effects of tetrasomy and, 59–60; response to ligand concentrations and, 108; of whole chromosome, 33; *see also specific chromosomes involved and specific trisomies*
- trisomy 6p, 51
- trisomy 6q, 51
- trisomy 8, malignancies and, 351
- trisomy 11q, partial, 51
- trisomy 13: critical zone for, 51; growth rate of cells with, 176; hemoglobins in human newborns with, 138–9; muscular anomalies and, 178; pathology of, 179; *see also chromosome 13*
- trisomy 15 in mouse lymphoma and leukemia, 355–9, 375
- trisomy 18: duplications of 18q11 and, 51; muscular anomalies and, 178; pathology of, 179
- trisomy 21 (Down syndrome), 9, 57, 175, 180–3, 256, 303–6, 351; adrenergic system in, 279–80, 304; aging and, 309–11; Alzheimer disease and, 300, 306–11; animal models for, 311–13, 315–23; cell adhesion and, 298; cell transformation in, 277–9; cellular aggregation in, 281–2; cellular phenotype of, 271–3; cellular proliferation and, 272–3; chromosomal radiosensitivity in, 275; congenital cardiac malformations in, 297–9; DNA synthesis and, 272; fibroblasts and, 272–3, 279–80, 281–2; FTS and, 295–6; gene dosage effects and hormonal imbalance and, 259–73, 283; glutathione peroxidase and, 261–2, 263; IFRC and, 263–9; immunological defects and, 288, 290–7; induction of chromosomal aberrations in, 276–9; interferon- α receptor and, 154, 263–9; leukemia and, 273, 283, 284–8; lymphocytes in, 175, 273, 275, 277, 287, 290, 292, 294–5, 296–7; mortality rate and, 5; mouse trisomy 16 and, 216; muscle in, 302–3; mutagenic and carcinogenic sensitivities of cells in, 273, 274–80; myelin and, 305; neurobiology and, 303–6; nervous system and, 299–311; neuropathology of, 300–3, 311; PAIS and, 269–70; PFKL and, 270–1; PHA responses and, 290–2; platelet

Cambridge University Press

978-0-521-25464-9 - The Consequences of Chromosome Imbalance: Principles, Mechanisms, and Models

Charles J. Epstein

Index

[More information](#)486 *Index*trisomy 21 (*cont.*)

function in, 280–1; PRGS and, 269–70; repair of chromosomal aberrations in, 275; SOD-1 and, 256–9, 260–1, 275; thymus in, 295; tryptophan metabolism in, 280; zinc in, 296; *see also* chromosome 21

trisomy 22, 33–4

tryptophan metabolism, trisomy 21 and platelet serotonin and, 280–1

tumorigenicity in hybrid human cells, 129; *see also* carcinogenesis

twins, congenital malformations in identical, 371

type and countertype concept, 159–60, 190

uniplex state, gene dosage effect and, 65

uric acid, X-linked PRPP synthetase activity and production of, 98

variability in expression of genetic conditions, 183–4

viruses: induction of chromosome aberrations and cell transformations by, 277–9; SV40, 277, 363

Wilms tumor, 47, 343, 350

X-chromosome loci, noninactivation of, 326, 328–30

X-chromosome monosomy, 9, 332–6

X-chromosome(s): aneuploidy of, 244–6, 324–43; assessment of activity of, 203; expressing of, 325; gene dosage com-

pensation in, 79, 81, 84; gene dosage effect ratio and, 325; gene dosage effects on, 328–9; inactivation of (in excess of one), 60; inactivation of paternal, 325; inactivation and reactivation of entire, 326, 328; insertion of mouse chromosome 7 segment into, 99; Klinefelter syndrome and, 332; life cycle of the, 324–6; male germ cells with two, 332; mechanisms for adjusting gene products of, 79; nonoperative inactivation during oogenesis, 321; pentasomy of, 61; phenotypic mapping of, 336–7; polysomy of, 60; short stature and congenital malformations and, 332–6; steroid sulfatase (STS) and, 328–30; teratocarcinoma cells (mouse) to study expression and inactivation of, 233; tetrasomy of, 61; in triploidy, 202; Turner syndrome and, 332–6

Xenopus, gene dosage compensation in, 82

X-inactivation hypothesis, 177

X-linked conditions, variability in expression of, 184

X-linked enzymes, 96, 98

XO embryos, 342

XO human female, XO mouse and, 341–2

XO mouse and 45,X human, 343

Y chromosome(s), aneuploidy of, 333

yeast: gene dosage compensation in, 82; test for induction of aneuploidy in, 112

zinc in trisomy 21, 296

zygotes not surviving beyond implantation, 3